JPY 4,868.00
+3.75%Price chart
Sep 11Sep 16Sep 24Sep 29Oct 2Oct 7Oct 13Oct 16
Key dataOct 16, 2026
OpenJPY 4,900.00
From 52W high−7.12%
Volume1.24M
Market capJPY 1.37T
P/E (TTM)32.4x
P/S (TTM)1.6x
Div yield3.29%
Key dataOct 16, 2026
Open
JPY 4,900.00
From 52W high
−7.12%
Volume
1.24M
Market cap
JPY 1.37T
ValuationView details →
P/E (Fwd)
26.0x
EV/EBITDA
14.0x
P/E (TTM)
32.4x
RSI (14)
60.9
MomentumView details →
1D Return
+3.75%
YTD Return
+5.58%
Similar companies
Latest newsMore news →
The FDA approved Merck & Co.'s Welireg (belzutifan) in combination with Eisai's Lenvima (lenvatinib) for advanced clear-cell renal cell carcinoma following treatment with a PD-(L)1 inhibitor.22d agoEisai and Biogen received Japanese manufacturing and marketing approval for a subcutaneous injection formulation of their Alzheimer's drug lecanemab (brand name Leqembi), which can be administered at home once weekly with a dedicated pen injector.30d agoEisai announced that China approved LEQEMBI (lecanemab) subcutaneous formulation as an initiation treatment for early Alzheimer's disease, enabling at-home administration.44d ago